➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Dow
Mallinckrodt
Moodys
McKesson

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BCT197

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for BCT197

Trial ID Title Status Sponsor Phase Summary
NCT01332097 Safety & Efficacy of BCT197A2201 in Chronic Obstructive Pulmonary Disease (COPD) Patients Presenting With an Exacerbation Completed Novartis Pharmaceuticals Phase 2 This study will assess preliminary parameters of safety and efficacy of a single dose of BCT197 in patients with a Chronic Obstructive Pulmonary Disease (COPD) exacerbation.
NCT01336959 Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery Terminated Novartis Pharmaceuticals Phase 2 This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass.
NCT02700919 Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Recruiting Mereo BioPharma Phase 2 The purpose of this study is to compare the efficacy and safety of BCT197 when added on to standard of care in adult subjects with acute respiratory exacerbations of chronic obstructive pulmonary disease requiring hospitalization. Additionally, the study will characterize the pharmacokinetics of BCT197 in adults with COPD. The total duration of the study will be 26 weeks. Subjects will receive study treatment administration over a period of 5 days after randomization. It is expected that approximately 255 subjects will complete the study and follow-up.
NCT02926326 The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers Completed Mereo BioPharma Phase 1 An open-label, single-sequence study to evaluate the effect of azithromycin on BCT197 exposure in healthy male subjects.
NCT03498170 The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants Completed Mereo BioPharma Phase 1 An Open-label, 2-period, Single-sequence, Crossover Study to Evaluate the Effect of Multiple Oral Dosing of Itraconazole on BCT197 Systemic Exposure in Healthy Male Participants.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for BCT197

Condition Name

Condition Name for
Intervention Trials
Interaction 2
Pulmonary Disease, Chronic Obstructive 1
Chronic Obstructive Pulmonary Disease 1
Acute Kidney Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Lung Diseases, Obstructive 2
Lung Diseases 2
Pulmonary Disease, Chronic Obstructive 2
Chronic Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BCT197

Trials by Country

Trials by Country for
Location Trials
United States 20
United Kingdom 2
Bulgaria 2
Russian Federation 2
Romania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Florida 2
California 2
Pennsylvania 2
Texas 1
Iowa 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BCT197

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 3
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BCT197

Sponsor Name

Sponsor Name for
Sponsor Trials
Mereo BioPharma 3
Novartis Pharmaceuticals 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKesson
McKinsey
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.